FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway

[1]  O. Elemento,et al.  EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. , 2016, Cancer cell.

[2]  Jihong Han,et al.  JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms , 2016, Oncotarget.

[3]  Weiqun Peng,et al.  Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. , 2016, The Journal of clinical investigation.

[4]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[5]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[6]  S. Naber,et al.  NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. , 2014, Cancer research.

[7]  N. Brockdorff,et al.  Variant PRC1 Complex-Dependent H2A Ubiquitylation Drives PRC2 Recruitment and Polycomb Domain Formation , 2014, Cell.

[8]  Kristian Helin,et al.  Chromatin repressive complexes in stem cells, development, and cancer. , 2014, Cell stem cell.

[9]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[10]  C. Tam,et al.  High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone? , 2013, Leukemia & lymphoma.

[11]  K. Helin,et al.  Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. , 2013, Molecular cell.

[12]  Hao Wu,et al.  Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes , 2013, Nature Cell Biology.

[13]  P. Park,et al.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. , 2013, The Journal of clinical investigation.

[14]  C. Ponting,et al.  KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands , 2012, eLife.

[15]  K. Basso,et al.  Roles of BCL6 in normal and transformed germinal center B cells , 2012, Immunological reviews.

[16]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[17]  A. Conesa,et al.  Differential expression in RNA-seq: a matter of depth. , 2011, Genome research.

[18]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[19]  L. Gordon,et al.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. , 2011, Blood.

[20]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[21]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[22]  Q. Zeng,et al.  F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway , 2011, Cell Death and Differentiation.

[23]  Jin He,et al.  KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. , 2011, Blood.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  C. Allis,et al.  Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.

[26]  Alexander D. MacKerell,et al.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.

[27]  Kristian Helin,et al.  Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.

[28]  Y. Natkunam,et al.  Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. , 2009, Cancer research.

[29]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[30]  E. Kandel,et al.  Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB , 2009, Proceedings of the National Academy of Sciences.

[31]  Kenny Q. Ye,et al.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. , 2009, Blood.

[32]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[33]  Jürg Müller,et al.  Biochemical mechanisms of gene regulation by polycomb group protein complexes. , 2009, Current opinion in genetics & development.

[34]  S. Cook,et al.  Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.

[35]  J. Molkentin,et al.  DUSP6 (MKP3) Null Mice Show Enhanced ERK1/2 Phosphorylation at Baseline and Increased Myocyte Proliferation in the Heart Affecting Disease Susceptibility* , 2008, Journal of Biological Chemistry.

[36]  Y. Tsukada,et al.  The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15Ink4b , 2008, Nature Structural &Molecular Biology.

[37]  T. Furukawa,et al.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. , 2008, Carcinogenesis.

[38]  L. Staudt,et al.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.

[39]  J. Armitage How I treat patients with diffuse large B-cell lymphoma. , 2007, Blood.

[40]  C. Sánchez,et al.  Proteomics Analysis of Ring1B/Rnf2 Interactors Identifies a Novel Complex with the Fbxl10/Jhdm1B Histone Demethylase and the Bcl6 Interacting Corepressor*S , 2007, Molecular & Cellular Proteomics.

[41]  J. A. Wamstad,et al.  Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets , 2006, Molecular and Cellular Biology.

[42]  L. Platanias Map kinase signaling pathways and hematologic malignancies. , 2003, Blood.

[43]  F. Motoi,et al.  Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. , 2003, The American journal of pathology.

[44]  Mark W. Budwig,et al.  A Matter of Depth , 2003 .

[45]  E. Verdin,et al.  BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.

[46]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[47]  E. Zabarovsky,et al.  Tumor suppressor dual‐specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial‐mesenchymal transition (EMT)‐associated phenotype , 2012, International journal of cancer.

[48]  G. Collins The next generation. , 2006, Scientific American.

[49]  G. Davies,et al.  Knowns and Unknowns , 2003 .